CONGO will receive 70,000 doses of the Ervebo vaccine, which has been effective in past Ebola outbreaks, the World Health Organisation (WHO) and partners said.

The vaccine is licensed for use against Ebola virus, one of the viruses that cause Ebola disease, but not for Bundibugyo virus, which is responsible for the current outbreak which has so far killed 2,476 people out of the 5,208 confirmed cases.

WHO said in a statement that while it’s not known whether Ervebo may protect against the Bundibugyo virus, “early laboratory and animal data suggest it may provide some protection.”

The allocation includes 20,000 doses for a Phase 3 clinical trial to understand the impact of the vaccine on the Bundibugyo virus, the agency said. The remaining 50,000 doses will be used for front-line and health workers as recommended by WHO experts.

The outbreak raging in six provinces in eastern Congo has infected and killed more people at a greater speed than any other Ebola outbreak in history, and is spreading about three times faster compared to the 2014-2016 outbreak across west Africa — the deadliest Ebola outbreak on record with more than 11,000 deaths.

WHO director-general Tedros Adhanom Ghebreyesus called the approval “an important example of global solidarity in action.”